The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapy
European Archives of Oto-Rhino-Laryngology · 2024-09 · 281 (9) · 4789-4805
DOI: 10.1007/s00405-024-08574-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 06.05.2024. Verfasst von Sven Ole Sarnoch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. svenolesarnoch@icloud.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Biomarkers, Immunoglobulin E. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).
Abstract (Originalsprache)
Purpose
Since its release, Dupilumab has shown great results in treating severe uncontrolled CRSwNP. However, there is a lack of real-world data beyond 12 months of follow-up, and it is not clear to what extent biomarkers are appropriate for monitoring and predicting the Dupilumab therapy success. Hence, this study aims to analyze biomarkers for monitoring therapy, predicting therapy success and assess the effect of Dupilumab in real-world settings.
Methods
The follow-up was performed with 104 patients retrospectively up to 22 months, assessing SNOT-22, NPS, olfactometry, ACS, FEV-1, and blood biomarkers (total serum IgE, Eosinophils, ECP). Patients were divided into subgroups depending on their pretherapeutic biomarker levels and subsequent development was analyzed.
Results
There was substantially improvement in all clinical parameters up to 1 year and then continuously up to month 22. Patients with initially elevated baseline blood eosinophil counts (> 0.5 billion/L) had a trend of better SNOT-22 development after 1 year (− 12.19 points, p = 0.03). The course of total serum IgE showed moderate correlation with almost all clinical variables obtained. Therapy was well tolerated with only mild and transient adverse events.
Conclusion
Dupilumab has considerably reduced symptoms and disease severity even beyond 1 year of treatment, supporting its role as targeted and effective treatment option for CRSwNP. Our data shows that total serum IgE is a promising biomarker for the monitoring during the treatment with Dupilumab. Elevated pre-therapeutic serum eosinophil counts may be a predictor of good subjective response to therapy. Larger cohorts and a long-term-follow-up over years are needed to further consolidate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. svenolesarnoch@icloud.com.
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
- Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Förderung
- Universitätsklinikum Hamburg-Eppendorf (UKE)
Zitieren
APA
Sarnoch, S. O., Pepić, A., Schmitz, L., Becker, B., Betz, C., & Hoffmann, A. S. (2024). The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapy. European Archives of Oto-Rhino-Laryngology, 281(9), 4789-4805. https://doi.org/10.1007/s00405-024-08574-4
Vancouver
Sarnoch SO, Pepić A, Schmitz L, Becker B, Betz C, Hoffmann AS. The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapy. European Archives of Oto-Rhino-Laryngology. 2024;281(9):4789-4805. doi:10.1007/s00405-024-08574-4
BibTeX
@article{Sarnoch2024,
author = {Sarnoch, Sven Ole and Pepić, Amra and Schmitz, Lisa and Becker, Benjamin and Betz, Christian and Hoffmann, Anna-Sophie},
title = {The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapy},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
volume = {281},
number = {9},
pages = {4789--4805},
doi = {10.1007/s00405-024-08574-4}
}
EUVIMED